Alere Inc. (NYSE:ALR)‘s stock had its “hold” rating reissued by Canaccord Genuity in a research report issued on Tuesday. They presently have a $51.00 price target on the medical research company’s stock. Canaccord Genuity’s price target suggests a potential upside of 0.99% from the company’s current price.

Other equities analysts have also issued research reports about the company. Zacks Investment Research raised Alere from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. BidaskClub raised Alere from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. BTIG Research reissued a “hold” rating on shares of Alere in a research note on Wednesday, May 24th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $51.00 target price on shares of Alere in a research note on Thursday, June 1st. One analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. Alere presently has a consensus rating of “Hold” and a consensus target price of $48.00.

Shares of Alere (NYSE:ALR) traded down 0.109% during trading on Tuesday, reaching $50.445. The company had a trading volume of 570,644 shares. Alere has a 52-week low of $34.41 and a 52-week high of $50.64. The firm’s market capitalization is $4.42 billion. The company has a 50 day moving average of $49.61 and a 200-day moving average of $47.44.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/aleres-alr-hold-rating-reaffirmed-at-canaccord-genuity/1576296.html.

A number of large investors have recently added to or reduced their stakes in ALR. Goldman Sachs Group Inc. lifted its stake in Alere by 266.5% in the second quarter. Goldman Sachs Group Inc. now owns 2,797,035 shares of the medical research company’s stock valued at $140,383,000 after buying an additional 2,033,824 shares during the period. Renaissance Technologies LLC lifted its stake in Alere by 352.4% in the second quarter. Renaissance Technologies LLC now owns 2,231,924 shares of the medical research company’s stock valued at $112,020,000 after buying an additional 1,738,600 shares during the period. Farallon Capital Management LLC lifted its stake in Alere by 54.7% in the second quarter. Farallon Capital Management LLC now owns 4,350,000 shares of the medical research company’s stock valued at $218,327,000 after buying an additional 1,537,500 shares during the period. York Capital Management Global Advisors LLC lifted its stake in Alere by 469.6% in the second quarter. York Capital Management Global Advisors LLC now owns 1,755,511 shares of the medical research company’s stock valued at $88,109,000 after buying an additional 1,447,307 shares during the period. Finally, Cowen Inc. lifted its stake in Alere by 1,232.5% in the second quarter. Cowen Inc. now owns 1,361,342 shares of the medical research company’s stock valued at $68,326,000 after buying an additional 1,259,181 shares during the period. 88.76% of the stock is currently owned by hedge funds and other institutional investors.

Alere Company Profile

Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.

Analyst Recommendations for Alere (NYSE:ALR)

Receive News & Ratings for Alere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.